Story · Medicine & Biotech

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

6 outlets · first reported by 日経メディカル on · latest · 55 hours of coverage · 3 countries

The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved… (STAT News)

Coverage, in order

  1. first 日経メディカル Japan indie ja
    FDA declines to approve ivonescimab plus chemotherapy for EGFR-mutant NSCLC progressing after third-generation EGFR-TKI第3世代EGFR-TKI治療で増悪したEGFR変異陽性NSCLCに対するivonescimabと化学療法の併用療法をFDAは承認せず

    Summit Therapeutics announced the decision on 15 November.米Summit Therapeutics社は11月15日、第3世代EGFR-TKI治療で増悪したEGFR変異陽性進行非小細胞肺癌(NSCLC)に対する、抗PD-1/VEGF二重特異性抗体ivonescimab(SMT112、AK112)と化学療法(白金系抗癌薬ベースの2剤併用)の併用療法の申請について、米食品医薬品局(FDA)がCRL(Complete Response Letter)を発出したと発表した。FDAは、主要評価項目の1つである無増悪生存期間(PFS)は有意に改善したものの、全生存期間(OS)で統計学的有意差が確認されていないとして、現時点では承認しなかった。

  2. STAT News indie study
    STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

    The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved…

  3. Pharmaphorum UK indie
    FDA won't approve Summit, Akeso's ivonescimab

    FDA won't approve Summit, Akeso's ivonescimab Phil.Taylor Sun, 15/11/2026 - 18:23

  4. OncoDaily obscure study
    Tom Powles: Ivonescimab Plus Chemotherapy Faces FDA Rejection in TKI-Refractory Lung Cancer

    Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X: “Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer. The trial

  5. OncoDaily obscure study
    Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLC

    Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA

  6. OncoDaily obscure study
    Masahiro Torasawa: FDA Declines to Approve Ivonescimab Plus Chemotherapy For EGFR Mutated NSCLC

    Masahiro Torasawa, Medical Oncologist at Juntendo University, shared on X: “FDA declines to approve ivonescimab (PD-1 × VEGF) + chemotherapy for EGFR-mutated NSCLC after EGFR-TKI therapy. Despite significant PFS improvement

  7. NYT Well mainstream study
    F.D.A. Rejects Closely Watched Lung Cancer Drug From China

    This X-ray shows stage 1 cancer. Summit Therapeutics of Florida had been seeking to bring to the U.S. market a drug for lung cancer, called ivonescimab, that was invented in China.

  8. Healio indie
    FDA rejects ivonescimab application for NSCLC types

    The FDA issued a complete response letter to Summit Therapeutics stating it cannot approve the company’s biologic license application for ivonescimab as treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer. The company had submitted the application for ivonescimab…

  9. OncoDaily obscure
    FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results

    Summit Therapeutics announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its biologics license application for ivonescimab plus platinum-containing chemotherapy in previously treated, locally

  10. OncoDaily obscure
    Nicholas Hornstein: FDA Rejects Ivonescimab Despite PFS Benefit in EGFR-Mutant NSCLC

    Nicholas Hornstein, Gastrointestinal Medical Oncologist at Northwell Health Cancer Institute and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared on X: “Interesting weekend surprise.

  11. OncoDaily obscure study
    Aakash Desai: What Does the FDA Decision Mean for Ivonescimab in EGFR-Mutant NSCLC?

    Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on LinkedIn: “The FDA issued a complete response letter for ivonescimab (PD-1 × VEGF bispecific) + platinum chemotherapy in EGFR-mutant

  12. OncoDaily obscure
    FDA Withholds Ivonescimab Approval in EGFR-Mutant NSCLC: Why HARMONi’s PFS Benefit Was Not Enough

    The US Food and Drug Administration has issued a Complete Response Letter for ivonescimab plus platinum-based chemotherapy in EGFR-mutated advanced non-small-cell lung cancer following EGFR tyrosine kinase inhibitor treatment. Announced

  13. OncoDaily obscure
    Estela Rodriguez: FDA Declines to Approve Summit Therapeutics Ivonescimab For Lung Cancer

    Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared on X: “It’s been a weird week. Planes grounded, Outlook

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.